InMed featured in article published in BioMedWire on June 14, 2024
Excerpt:
INM-901 is currently being investigated for its potential in treating Alzheimer’s disease. Recent preclinical data showcased its positive pharmacological effects, demonstrating reduced neuroinflammation and improved neuronal function, among other promising outcomes. The small molecule drug, acting as a preferential signaling ligand for CB1/CB2, delivers improved retinal pigment epithelium integrity, neuroprotection, and photoreceptor improvement in an in vivo preclinical disease model.
“The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said Dr. Eric Hsu (https://ibn.fm/qUx1Z). “There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.”
Full article here in BioMedWire.
